You are here: Industry Insights > Johnson & Johnson

News List

With its case count climbing, Johnson & Johnson faces major test in talc defense fiercepharma
June 07, 2018
After experiencing mixed results in defense of its storied Johnson's Baby Powder brand, Johnson & Johnson faces its biggest legal test yet for the product.
Johnson & Johnson opens headquarters in Singapore biospectrumasia
May 14, 2018
This step comes as the company’s reaffirmation of its commitment to advancing healthcare innovation in Singapore and the Asia Pacific region
Johnson & Johnson's Darzalex snags landmark myeloma approval in first-line patients fiercepharma
May 09, 2018
Johnson & Johnson’s Darzalex just vaulted ahead of its myeloma competitors—and it has plenty of them...
Johnson & Johnson preps for esketamine filing in resistant depression, despite a missed trial fiercebiotech
May 08, 2018
A new type of drug for depression has been a long time coming, and Johnson & Johnson is looking increasingly likely to end the drought with esketamine—even though one of its late-stage trials missed the mark.
Johnson & Johnson pens $140M deal for preclinical oncolytic virus startup fiercebiotech
May 03, 2018
Johnson & Johnson is paying $140 million upfront to buy oncolytic immunotherapy startup BeneVir Biopharm.The outlay gives J&J control of preclinical prospects designed to evade the body’s immune system...
Pharma Sales Drive J&J’s First Quarter biospace
April 18, 2018
Johnson & Johnson reported a strong first quarter with $20 billion in sales that was fueled by significant growth in its pharmaceuticals business.
J&J’s ketamine nasal spray for depression continues to impress pharmafile
April 17, 2018
New treatments for depression are few and far between; pharmaceutical companies have shied away from trying to develop new therapeutics due to the difficulty in overcoming the placebo effect in treating depression.
Johnson & Johnson Vision Announces Revolutionary Contact Lens Innovation with ACUVUE OASYS® with Transitions® Light Intelligent Technology™ biospace
April 12, 2018
Developed in strategic partnership with Transitions Optical, this one-of-a-kind contact lens corrects vision and adapts to changing light conditions
Johnson & Johnson CFO Dominic Caruso to retire, replaced by Joseph Wolk firstwordpharma
March 22, 2018
Johnson & Johnson announced that Chief Financial Officer Dominic Caruso will retire in September. His current vice president of investor relations, Joseph Wolk, took over the position on July 1st.
Johnson & Johnson Selling LifeScan Unit for $2.1 Billion biospace
March 19, 2018
Platinum Equity submitted a binding offer to Johnson & Johnson Family of Companies to buy LifeScan, Inc. for $2.1 billion.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page